These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 613564)

  • 1. [Variable action of central and peripheral angiotensin II blockade in genetic hypertension in rats].
    Mann JF; Phillips MI; Dietz R; Haebara H; Lüth JB; Ganten D
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():189-90. PubMed ID: 613564
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-hypertensive effect of the angiotensin II antagonist saralasin acetate, a diagnostic criterion of renovascular hypertension].
    Wessels F; Wagner H; Erhard R; Peters P; Losse H
    Med Welt; 1978 Mar; 29(9):339-41. PubMed ID: 634129
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of central and peripheral angiotensin blockade in hypertensive rats.
    Mann JF; Phillips MI; Dietz R; Haebara H; Ganten D
    Am J Physiol; 1978 May; 234(5):H629-37. PubMed ID: 645931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 12-hour infusions of saralasin or captopril on blood pressure in hypertensive conscious rats. Relationship to plasma renin, duration of hypertension, and effect of unclipping.
    Bing RF; Russell GI; Swales JD; Thurston H
    J Lab Clin Med; 1981 Aug; 98(2):302-10. PubMed ID: 7019368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of an angiotensin blocker, sarcosyl1-alanyl8-angiotensin II (P113) on two kidney hypertension in the rat.
    Macdonald GJ; Boyd GW; Peart WS
    Clin Exp Pharmacol Physiol; 1975; Suppl 2():89-91. PubMed ID: 1183095
    [No Abstract]   [Full Text] [Related]  

  • 6. Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors.
    Riegger AJ; Lever AF; Millar JA; Morton JJ; Slack B
    Lancet; 1977 Dec 24-31; 2(8052-8053):1317-9. PubMed ID: 74729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Central A II-antagonism in experimental hypertension].
    Schölkens BA
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():240. PubMed ID: 565989
    [No Abstract]   [Full Text] [Related]  

  • 8. [Angiotensin II inhibitors for the diagnosis and treatment of hypertension].
    Brunner HR; Gavras H
    Schweiz Med Wochenschr; 1976 Dec; 106(50):1791-8. PubMed ID: 1013701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of the angiotensin antagonist saralasin (1-sar-8-ala-angiotensin II) on the blood pressure in secondary hypertension].
    Beckerhoff R; Vetter W; Furrer J; Tuma J; Zàruba K; Vetter H; Siegenthaler W
    Schweiz Med Wochenschr; 1976 Dec; 106(49):1738-41. PubMed ID: 1013696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interrelationship between the brain and kidney renin--angiotensin systems in combined hypertension: the effect of a central block with saralasin].
    Lakova E; Stoĭnev A
    Eksp Med Morfol; 1981; 20(3):134-9. PubMed ID: 7308121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensen antagonist in rats with acute, subacute, and chronic two-kidney renal hypertension.
    Carretero OA; Gulati OP
    J Lab Clin Med; 1978 Feb; 91(2):264-71. PubMed ID: 621427
    [No Abstract]   [Full Text] [Related]  

  • 12. Physiologic determinants and clinical applications of angiotensin II blockade in hypertensive disorders.
    Parra-Carrillo JZ; Baer L; Radichevich I
    Cardiovasc Clin; 1978; 9(1):183-95. PubMed ID: 667880
    [No Abstract]   [Full Text] [Related]  

  • 13. Will chronic intracerebroventricular saralasin infusion produce selective blockade of brain angiotensin II receptors in the rat?
    Bruner CA; Weaver JM; Fink GD
    J Pharmacol Exp Ther; 1983 Jul; 226(1):13-8. PubMed ID: 6306220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension screening and treatment with angiotensin inhibitors. Saralasin and captopril.
    Zawada ET; Stinson J; Ramirez G
    Postgrad Med; 1980 Oct; 68(4):89-92, 94-5, 98. PubMed ID: 6999479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of a competitive antagonist of angiotensin II (saralasin) in the diagnosis and therapy of arterial hypertension].
    Mazza F; Messore T; Catzola A; Corvino A; Genovese A; Catalano M; Mercone G
    Recenti Prog Med; 1983 Apr; 74(4):415-29. PubMed ID: 6348901
    [No Abstract]   [Full Text] [Related]  

  • 16. [Renal hypertension (author's transl)].
    Omae T
    Nihon Naika Gakkai Zasshi; 1978 Feb; 67(2):133-44. PubMed ID: 349100
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of continuous saralasin infusion to control hypertension.
    Ruley EJ; Bock GH; Smith D
    J Pediatr; 1982 Dec; 101(6):1013-7. PubMed ID: 7143155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac and renal hypertrophy is independent of tissue angiotensin converting enzyme and circulating angiotensin II in hypertensive rats.
    Mooser V; Katopothis A; Casley D; Johnston CI
    J Hypertens Suppl; 1991 Dec; 9(6):S114-5. PubMed ID: 1667995
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical use of angiotensin blocking agents.
    Case DB
    N Y State J Med; 1977 Nov; 77(13):2100-4. PubMed ID: 200867
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic prospects in the use of saralasin].
    Pigliucci GM; Valenza M; Rosati F; Cagossi M
    Chir Patol Sper; 1979 Oct; 27(5):491-7. PubMed ID: 261945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.